



SIGACHI LABORATORIES LIMITED

Corporate Office: 402, Raghava Ratna Towers,

Chirag Ali Lane, Hyderabad - 500 001. (INDIA)

Ph. : 040-23204230, 23204273 E-mail: sigachilaboratories@yahoo.co.in

CIN: L24230TG1994PLC018786 GSTIN: 36AACCS8220M1Z4

Date: 15.09.2020

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th Floor
Plot No.62, G- Block, Opp Trident Hotel,
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 098

Dear Sir,

Sub: outcome of the Board Meeting held today i.e., on 15th September, 2020 -- Reg.

We wish to inform you that the Board of Directors at its Meeting held today i.e., 15th September, 2020 have approved the Unaudited Financial Results for the Quarter ended 30th June, 2020. We are herewith enclosing the Unaudited Financial Results for the Quarter ended 30th June, 2020 along with Limited Review Report of the Statutory Auditors for your kind perusal and records

Kindly acknowledge the receipt of the same.

Thanking you,

Yours faithfully,
For Sigachi Laboratories Limited

LEKHA SAI
SURAPANE
NI

Digitally signed by
LEKHA SAI
SURAPANENI
Date: 2020.09.15
16:31:49 +05'30'

(Lekha Sai Surapaneni)
Company Secretary

Meeting Commenced at 4:00 P.M.

Meeting Concluded at 4:30 P.M.

SIGACHI LABORATORIES LIMITED

CIN:L24230TG1994PLC018786

Regd.Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230/23204273,

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in

Statement of Unaudited Financial Results For The Quarter Ended 30th June, 2020

(Rs. In Lakhs)

Sl.No	Particulars	Quarter ended			Year ended
		30.06.2020	30.06.2019	31.03.2020	31.03.2020
		(Unaudited)	(Unaudited)	(Audited)	(Audited)
1	Revenue from operations	84.61	26.97	(45.05)	66.51
2	Other income	1.54	50.30	12.49	106.07
3	Total Income (1+2)	86.15	77.27	(32.56)	172.58
4	Expenses				
	a) Cost of materials consumed	-	-	-	-
	b) Purchase of Stock-in-Trade	-	-	-	-
	c) Change in Inventories	-	-	-	-
	d) Employee benefits expense	5.30	5.91	6.92	27.99
	e) Finance costs	-	-	-	-
	f) Depreciation and amortization expense	4.14	3.56	4.06	15.32
	g) Other expenses	2.68	7.06	3.46	12.64
	Total Expenses	12.12	16.53	14.44	55.96
5	Profit/(Loss) before exceptional and extraordinary items and tax (3-4)	74.03	60.74	(47.00)	116.62
6	Exceptional Items	-	-	-	-
7	Profit/(Loss) before extraordinary items and tax (5-6)	74.03	60.74	(47.00)	116.62
8	Extraordinary items	-	-	-	-
9	Profit/(Loss) before tax (7-8)	74.03	60.74	(47.00)	116.62
10	Tax expense				
	(a) Current tax	5.75	5.25	20.02	44.03
	(b) Deferred tax	0.20	0.14	0.22	1.94
	Total Tax Expense	5.95	5.39	20.24	45.97
11	Profit/(Loss) for the Period/Year (9-10)	68.08	55.35	(67.24)	70.65
12	Other Comprehensive income (OCI)				
	(a) Items that will not be reclassified to Profit or (Loss)	158.32	(13.93)	(227.93)	(226.96)
	(b) Items that will be reclassified to Profit or (Loss)	-	-	-	-
	Total Other Comprehensive income	158.32	(13.93)	(227.93)	(226.96)
	Total Comprehensive income (11+12)	226.40	41.42	(295.17)	(156.31)
13	Paid-up Equity Share Capital (Face Value Rs.10/- per share)	675.31	675.31	675.31	675.31
14	Other Equity	-	-	-	1,256.34
15	Earnings per equity share (of Rs.10/- each) (not annualized (Rs.))				
	(1) Basic	1.01	0.82	(1.00)	1.05
	(2) Diluted	1.01	0.82	(1.00)	1.05

Segment wise Revenue, Results and Capital Employed for the Quarter Ended 30th June, 2020

(Rs.in Lakhs)

Sl.No	Particulars	Quarter ended			Year ended
		30.06.2020	30.06.2019	31.03.2020	31.03.2020
		(Unaudited)	(Unaudited)	(Audited)	(Audited)
1	Segment Revenue				
	a) Bulk Drugs and Intermediates (Lease Rents)	19.00	18.00	38.00	110.50
	b) Investments	67.15	59.27	(70.56)	62.08
	Total	86.15	77.27	(32.56)	172.58
	Less: Inter Segment Revenue	-	-	-	-
	Net sales/Income from Operations	86.15	77.27	(32.56)	172.58
2	Segment Results Profit/(Loss) before tax and finance Costs from each segment				
	a) Bulk Drugs and Intermediates (Lease Rents)	14.33	13.43	33.39	93.55
	b) Investments	67.15	59.27	(70.56)	62.07
	Total	81.48	72.70	(37.17)	155.62
	Less: (i) Finance Costs	-	-	-	-
	(ii) Other Un-allocable Expenditure net off	7.45	11.97	9.83	39.00
	(iii) Un-allocable income	-	-	-	-
	Total Profit Before Tax	74.03	60.74	(47.00)	116.62
3	Capital Employed				
	(Segment assets – Segment liabilities)				
	a) Bulk Drugs and Intermediates	578.89	469.76	576.05	576.05
	b) Investments	1,634.90	1,711.21	1,411.34	1,411.34
	Total	2,213.79	2,180.97	1,987.39	1,987.39

Notes :

- The above Financial results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their respective Meetings held on 15th September, 2020.
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The outbreak of COVID-19 continues to spread across the globe and India, which has contributed to a significant decline and volatility in global and Indian Financial Markets and a significant decrease in the economic activities. On 11th March 2020, the COVID-19 outbreak was declared as a global pandemic by the World Health Organisation. On 24th March, 2020 the Indian Government had announced a strict 21 day lockdown which kept on getting extended across the country with gradual and modest relaxations. Given the dynamic nature of the pandemic situation, the carrying value of the Company's investments and loans as at June 30, 2020, may be affected by the severity and duration of the outbreak.; however the Company believes that it has taken into account all the possible impact of known events arising out of COVID-19 pandemic in the preparation of financial results resulting out of fair valuation of these investments. However the impact assessment of COVID-19 is a continuing process given its nature and duration. The Company will continue to monitor for any material changes to future economic conditions.
- Previous year/period figures have been recasted/regrouped/reclassified wherever necessary to make them comparable with current year/period figures.

By Order of the Board
for Sigachi Laboratories Limited

T
RAJASEKHAR
Digitally signed by
T RAJASEKHAR
Date: 2020.09.15
16:33:09 +05'30'

(T.R.Sekhar)
Executive Director
DIN:02943146

Place : Hyderabad
Date : 15.09.2020

INDEPENDENT AUDITORS' REVIEW REPORT

To
The Board of Directors,
Sigachi Laboratories Limited,

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Sigachi Laboratories Limited ("the company") for the quarter ended 30th June, 2020 ("the statement") being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated 5th July, 2016. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting ("Ind As 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these interim financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of interim Financial Information performed by the Independent Auditor of the Entity', issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the interim financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other accounting principles generally accepted, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with relevant SEBI Circulars including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date : 15.09.2020

Place : Hyderabad



For Niranjana & Narayan
Chartered Accountants

FRN : 005899S

M. Niranjana

Partner-Memb. No. 029552

UDIN: 20029552AAAAIY7664